The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Prostatic Neoplasms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Prostatic Neoplasms


Psychiatry related information on Prostatic Neoplasms


High impact information on Prostatic Neoplasms

  • This article reviews the salient features of PSA, with particular emphasis on strategies to improve its utility in the diagnosis of prostate cancer [10].
  • The ACS National Prostate Cancer Detection Project was established in 1987 to demonstrate the feasibility of early detection as a cancer control strategy for prostate cancer [11].
  • In summary, the 1997 revision of the ACS guideline for the early detection of prostate cancer is based on knowledge gained by a critical analysis of experience since the original version of 1992 [12].
  • The benefit and cost of prostate cancer early detection. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project [13].
  • Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer [14].

Chemical compound and disease context of Prostatic Neoplasms


Biological context of Prostatic Neoplasms


Anatomical context of Prostatic Neoplasms


Gene context of Prostatic Neoplasms


Analytical, diagnostic and therapeutic context of Prostatic Neoplasms


  1. Advances in prostate cancer chemotherapy: a new era begins. Pienta, K.J., Smith, D.C. CA: a cancer journal for clinicians. (2005) [Pubmed]
  2. Megestrol acetate for the prevention of hot flashes. Loprinzi, C.L., Michalak, J.C., Quella, S.K., O'Fallon, J.R., Hatfield, A.K., Nelimark, R.A., Dose, A.M., Fischer, T., Johnson, C., Klatt, N.E. N. Engl. J. Med. (1994) [Pubmed]
  3. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Gayther, S.A., Mangion, J., Russell, P., Seal, S., Barfoot, R., Ponder, B.A., Stratton, M.R., Easton, D. Nat. Genet. (1997) [Pubmed]
  4. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Klein, K.A., Reiter, R.E., Redula, J., Moradi, H., Zhu, X.L., Brothman, A.R., Lamb, D.J., Marcelli, M., Belldegrun, A., Witte, O.N., Sawyers, C.L. Nat. Med. (1997) [Pubmed]
  5. Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer. Weber, D.C., Bieri, S., Kurtz, J.M., Miralbell, R. J. Clin. Oncol. (1999) [Pubmed]
  6. Hypothyroidism associated with aminoglutethimide in patients with prostate cancer. Figg, W.D., Thibault, A., Sartor, A.O., Mays, D., Headlee, D., Calis, K.A., Cooper, M.R. Arch. Intern. Med. (1994) [Pubmed]
  7. The mean 1300-1600 h plasma cortisol concentration as a diagnostic test for hypercortisolism. Halbreich, U., Zumoff, B., Kream, J., Fukushima, D.K. J. Clin. Endocrinol. Metab. (1982) [Pubmed]
  8. Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Patel, A.V., Rodriguez, C., Jacobs, E.J., Solomon, L., Thun, M.J., Calle, E.E. Cancer Epidemiol. Biomarkers Prev. (2005) [Pubmed]
  9. Associations of demographic and health-related characteristics with prostate cancer screening in Washington State. Close, D.R., Kristal, A.R., Li, S., Patterson, R.E., White, E. Cancer Epidemiol. Biomarkers Prev. (1998) [Pubmed]
  10. Prostate-specific antigen: current status. Brawer, M.K. CA: a cancer journal for clinicians. (1999) [Pubmed]
  11. The American Cancer Society National Prostate Cancer Detection Project and National patterns of prostate cancer detection and treatment. Mettlin, C. CA: a cancer journal for clinicians. (1997) [Pubmed]
  12. American Cancer Society guideline for the early detection of prostate cancer: update 1997. von Eschenbach, A., Ho, R., Murphy, G.P., Cunningham, M., Lins, N. CA: a cancer journal for clinicians. (1997) [Pubmed]
  13. The benefit and cost of prostate cancer early detection. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Littrup, P.J., Goodman, A.C., Mettlin, C.J. CA: a cancer journal for clinicians. (1993) [Pubmed]
  14. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Sun, X., Frierson, H.F., Chen, C., Li, C., Ran, Q., Otto, K.B., Cantarel, B.L., Cantarel, B.M., Vessella, R.L., Gao, A.C., Petros, J., Miura, Y., Simons, J.W., Dong, J.T. Nat. Genet. (2005) [Pubmed]
  15. The current state of hormonal therapy for prostate cancer. Hellerstedt, B.A., Pienta, K.J. CA: a cancer journal for clinicians. (2002) [Pubmed]
  16. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. DiPaola, R.S., Zhang, H., Lambert, G.H., Meeker, R., Licitra, E., Rafi, M.M., Zhu, B.T., Spaulding, H., Goodin, S., Toledano, M.B., Hait, W.N., Gallo, M.A. N. Engl. J. Med. (1998) [Pubmed]
  17. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. Eisenberger, M.A., Blumenstein, B.A., Crawford, E.D., Miller, G., McLeod, D.G., Loehrer, P.J., Wilding, G., Sears, K., Culkin, D.J., Thompson, I.M., Bueschen, A.J., Lowe, B.A. N. Engl. J. Med. (1998) [Pubmed]
  18. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. Smith, M.R., McGovern, F.J., Zietman, A.L., Fallon, M.A., Hayden, D.L., Schoenfeld, D.A., Kantoff, P.W., Finkelstein, J.S. N. Engl. J. Med. (2001) [Pubmed]
  19. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. Bolla, M., Gonzalez, D., Warde, P., Dubois, J.B., Mirimanoff, R.O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., Collette, L., Pierart, M. N. Engl. J. Med. (1997) [Pubmed]
  20. Dietary factors of one-carbon metabolism and prostate cancer risk. Weinstein, S.J., Stolzenberg-Solomon, R., Pietinen, P., Taylor, P.R., Virtamo, J., Albanes, D. Am. J. Clin. Nutr. (2006) [Pubmed]
  21. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Key, T.J., Appleby, P.N., Allen, N.E., Travis, R.C., Roddam, A.W., Jenab, M., Egevad, L., Tjønneland, A., Johnsen, N.F., Overvad, K., Linseisen, J., Rohrmann, S., Boeing, H., Pischon, T., Psaltopoulou, T., Trichopoulou, A., Trichopoulos, D., Palli, D., Vineis, P., Tumino, R., Berrino, F., Kiemeney, L., Bueno-de-Mesquita, H.B., Quirós, J.R., González, C.A., Martinez, C., Larrañaga, N., Chirlaque, M.D., Ardanaz, E., Stattin, P., Hallmans, G., Khaw, K.T., Bingham, S., Slimani, N., Ferrari, P., Rinaldi, S., Riboli, E. Am. J. Clin. Nutr. (2007) [Pubmed]
  22. Protein 4.1B suppresses prostate cancer progression and metastasis. Wong, S.Y., Haack, H., Kissil, J.L., Barry, M., Bronson, R.T., Shen, S.S., Whittaker, C.A., Crowley, D., Hynes, R.O. Proc. Natl. Acad. Sci. U.S.A. (2007) [Pubmed]
  23. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Hudson, T.S., Hartle, D.K., Hursting, S.D., Nunez, N.P., Wang, T.T., Young, H.A., Arany, P., Green, J.E. Cancer Res. (2007) [Pubmed]
  24. Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3. Chen, L., Mooso, B.A., Jathal, M.K., Madhav, A., Johnson, S.D., van Spyk, E., Mikhailova, M., Zierenberg-Ripoll, A., Xue, L., Vinall, R.L., Devere White, R.W., Ghosh, P.M. Clin. Cancer Res. (2011) [Pubmed]
  25. Overcoming chemotherapy resistance in prostate cancer. Madan, R.A., Pal, S.K., Sartor, O., Dahut, W.L. Clin. Cancer Res. (2011) [Pubmed]
  26. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Di Cristofano, A., De Acetis, M., Koff, A., Cordon-Cardo, C., Pandolfi, P.P. Nat. Genet. (2001) [Pubmed]
  27. Mutation of the MXI1 gene in prostate cancer. Eagle, L.R., Yin, X., Brothman, A.R., Williams, B.J., Atkin, N.B., Prochownik, E.V. Nat. Genet. (1995) [Pubmed]
  28. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Xu, J., Zheng, S.L., Komiya, A., Mychaleckyj, J.C., Isaacs, S.D., Hu, J.J., Sterling, D., Lange, E.M., Hawkins, G.A., Turner, A., Ewing, C.M., Faith, D.A., Johnson, J.R., Suzuki, H., Bujnovszky, P., Wiley, K.E., DeMarzo, A.M., Bova, G.S., Chang, B., Hall, M.C., McCullough, D.L., Partin, A.W., Kassabian, V.S., Carpten, J.D., Bailey-Wilson, J.E., Trent, J.M., Ohar, J., Bleecker, E.R., Walsh, P.C., Isaacs, W.B., Meyers, D.A. Nat. Genet. (2002) [Pubmed]
  29. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Huusko, P., Ponciano-Jackson, D., Wolf, M., Kiefer, J.A., Azorsa, D.O., Tuzmen, S., Weaver, D., Robbins, C., Moses, T., Allinen, M., Hautaniemi, S., Chen, Y., Elkahloun, A., Basik, M., Bova, G.S., Bubendorf, L., Lugli, A., Sauter, G., Schleutker, J., Ozcelik, H., Elowe, S., Pawson, T., Trent, J.M., Carpten, J.D., Kallioniemi, O.P., Mousses, S. Nat. Genet. (2004) [Pubmed]
  30. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. Taplin, M.E., Bubley, G.J., Shuster, T.D., Frantz, M.E., Spooner, A.E., Ogata, G.K., Keer, H.N., Balk, S.P. N. Engl. J. Med. (1995) [Pubmed]
  31. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nair, S.K., Heiser, A., Boczkowski, D., Majumdar, A., Naoe, M., Lebkowski, J.S., Vieweg, J., Gilboa, E. Nat. Med. (2000) [Pubmed]
  32. Biological determinants of cancer progression in men with prostate cancer. Stamey, T.A., McNeal, J.E., Yemoto, C.M., Sigal, B.M., Johnstone, I.M. JAMA (1999) [Pubmed]
  33. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. Sumitomo, M., Shen, R., Walburg, M., Dai, J., Geng, Y., Navarro, D., Boileau, G., Papandreou, C.N., Giancotti, F.G., Knudsen, B., Nanus, D.M. J. Clin. Invest. (2000) [Pubmed]
  34. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M.A., Lallas, C.D., Dahm, P., Niedzwiecki, D., Gilboa, E., Vieweg, J. J. Clin. Invest. (2002) [Pubmed]
  35. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Casey, G., Neville, P.J., Plummer, S.J., Xiang, Y., Krumroy, L.M., Klein, E.A., Catalona, W.J., Nupponen, N., Carpten, J.D., Trent, J.M., Silverman, R.H., Witte, J.S. Nat. Genet. (2002) [Pubmed]
  36. A candidate prostate cancer susceptibility gene at chromosome 17p. Tavtigian, S.V., Simard, J., Teng, D.H., Abtin, V., Baumgard, M., Beck, A., Camp, N.J., Carillo, A.R., Chen, Y., Dayananth, P., Desrochers, M., Dumont, M., Farnham, J.M., Frank, D., Frye, C., Ghaffari, S., Gupte, J.S., Hu, R., Iliev, D., Janecki, T., Kort, E.N., Laity, K.E., Leavitt, A., Leblanc, G., McArthur-Morrison, J., Pederson, A., Penn, B., Peterson, K.T., Reid, J.E., Richards, S., Schroeder, M., Smith, R., Snyder, S.C., Swedlund, B., Swensen, J., Thomas, A., Tranchant, M., Woodland, A.M., Labrie, F., Skolnick, M.H., Neuhausen, S., Rommens, J., Cannon-Albright, L.A. Nat. Genet. (2001) [Pubmed]
  37. No association of germline alteration of MSR1 with prostate cancer risk. Wang, L., McDonnell, S.K., Cunningham, J.M., Hebbring, S., Jacobsen, S.J., Cerhan, J.R., Slager, S.L., Blute, M.L., Schaid, D.J., Thibodeau, S.N. Nat. Genet. (2003) [Pubmed]
  38. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Patrawala, L., Calhoun-Davis, T., Schneider-Broussard, R., Tang, D.G. Cancer Res. (2007) [Pubmed]
  39. 17beta-estradiol up-regulates the insulin-like growth factor receptor through a nongenotropic pathway in prostate cancer cells. Pandini, G., Genua, M., Frasca, F., Squatrito, S., Vigneri, R., Belfiore, A. Cancer Res. (2007) [Pubmed]
  40. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Gu, X., Zerbini, L.F., Otu, H.H., Bhasin, M., Yang, Q., Joseph, M.G., Grall, F., Onatunde, T., Correa, R.G., Libermann, T.A. Cancer Res. (2007) [Pubmed]
  41. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. Li, Z.G., Mathew, P., Yang, J., Starbuck, M.W., Zurita, A.J., Liu, J., Sikes, C., Multani, A.S., Efstathiou, E., Lopez, A., Wang, J., Fanning, T.V., Prieto, V.G., Kundra, V., Vazquez, E.S., Troncoso, P., Raymond, A.K., Logothetis, C.J., Lin, S.H., Maity, S., Navone, N.M. J. Clin. Invest. (2008) [Pubmed]
  42. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Agalliu, I., Gern, R., Leanza, S., Burk, R.D. Clin. Cancer Res. (2009) [Pubmed]
  43. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Sun, T., Lee, G.S., Oh, W.K., Pomerantz, M., Yang, M., Xie, W., Freedman, M.L., Kantoff, P.W. Clin. Cancer Res. (2010) [Pubmed]
  44. Activation of β-Catenin Signaling in Androgen Receptor-Negative Prostate Cancer Cells. Wan, X., Liu, J., Lu, J.F., Tzelepi, V., Yang, J., Starbuck, M.W., Diao, L., Wang, J., Efstathiou, E., Vazquez, E.S., Troncoso, P., Maity, S.N., Navone, N.M. Clin. Cancer Res. (2012) [Pubmed]
  45. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer. Spitz, I.M., Chertin, B., Lindenberg, T., Farkas, A. N. Engl. J. Med. (1999) [Pubmed]
  46. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., Kallioniemi, O.P. Nat. Genet. (1995) [Pubmed]
  47. Molecular determinants of resistance to antiandrogen therapy. Chen, C.D., Welsbie, D.S., Tran, C., Baek, S.H., Chen, R., Vessella, R., Rosenfeld, M.G., Sawyers, C.L. Nat. Med. (2004) [Pubmed]
  48. The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Dixon, S.C., Knopf, K.B., Figg, W.D. Pharmacol. Rev. (2001) [Pubmed]
WikiGenes - Universities